Oramed Pharmaceuticals (NSDQ:ORMP) announced today that it is forming a joint venture to develop novel oral COVID-19 vaccines.
New York-based Oramed entered into definitive agreements to form Oravax Medical, which is based on Oramed’s proprietary POD (protein oral delivery) technology and Premas Biotech’s novel vaccine technology, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.
Filed Under: clinical trials, Drug Delivery, Drug Discovery, Drug Discovery and Development, Infectious Disease
